23948sdkhjf
Köp Köp åtkomst
  • {{ window.visitor.ipAccess.corporateClient.name }}

  • Welcome to our Corporate client solution

    Your IP is registered with the company mentioned above and provides access to Life Science Sweden.

  • Click here to go to sign-up
  • {{ window.visitor.ipAccess.corporateClient.name }}

  • Welcome to our Corporate client solution

    Your IP is registered with the company mentioned above and provides access to Life Science Sweden.

  • Click here to go to sign-up
Logga in eller skapa för att spara artiklar
Få tillgång till allt innehåll på Life Science Sweden
Ingen bindningstid eller kortinformation krävs
Prova Life Science Sweden nu
Gäller endast personlig prenumeration.
Kontakta oss för en företagslösning.
News in English

Tau-targeted Alzheimer's drug gets Fast Track designation in the USA

Biogen's Alzheimer's candidate BIIB080 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).

 BIIB080 is currently being evaluated in Phase II as a treatment for patients in the early stages of Alzheimer's disease. It is an oligonucleotide targeting the tau protein, which is associated with changes in the brain linked to Alzheimer's disease.

In early stage clinical studies, BIIB080 has shown positive results by reducing tau protein levels in cerebrospinal fluid and improving cognitive functions in patients in the early stages of the disease, according to Biogen.

BREAKING
{{ article.headline }}
0.125